Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: A report from the American College of Surgeons Oncology Group (ACOSOG) special populations committee

Lisa A. Newman, Cheryl T. Lee, Lina Patel Parekh, Andrew K. Stewart, Charles R. Thomas, Robert A. Beltran, Anthony Lucci, Bettye Green, David Ota, Heidi Nelson

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

BACKGROUND. Disparities in cancer outcome among different subsets of the American population related to ethnic background have been well documented. Clinical trials represent the most powerful strategy for improving cancer treatments, but racial and ethnic minority patients are frequently underrepresented among patients accrued to these protocols. Proof of comparable efficacy for a promising cancer therapy in different groups of patients requires diversity in the clinical trial populations so that study results will be generalizable. Appropriate targets for accrual of minority ethnicity patients have not previously been defined. METHODS. The National Cancer Database (NCDB) is maintained jointly by the American Cancer Society and the American College of Surgeons. Information submitted by tumor registries throughout the United States represents an estimated 70% of newly diagnosed cancer cases. The authors analyzed NCDB reports on ethnic distribution of patients with breast, prostate, nonsmall cell lung, and colorectal cancer, stratified by stage of disease at diagnosis. RESULTS. African Americans with cancer of the breast and prostate had the most notable patterns of disproportionate representation among populations with advanced-stage disease. The authors compiled a table of suggested accrual targets for selected solid-organ cancers based on NCDB stage-specific reports. CONCLUSIONS. Clinical trial results will be more meaningful if participating patients reflect the site- and stage-specific populations that are under study. The authors recommended that clinical trial investigators incorporate accrual targets for minority ethnicity populations into the study design.

Original languageEnglish (US)
Pages (from-to)188-195
Number of pages8
JournalCancer
Volume106
Issue number1
DOIs
StatePublished - Jan 1 2006

Fingerprint

Population Groups
Clinical Trials
Databases
Neoplasms
Population
Non-Small Cell Lung Carcinoma
African Americans
Registries
Prostate
Colorectal Neoplasms
Prostatic Neoplasms
Breast
Research Personnel
Breast Neoplasms
Therapeutics

Keywords

  • Breast cancer
  • Colorectal cancer
  • Disease stage
  • Ethnicity
  • Minority
  • National Cancer Data Base
  • Nonsmall cell lung cancer
  • Prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients : A report from the American College of Surgeons Oncology Group (ACOSOG) special populations committee. / Newman, Lisa A.; Lee, Cheryl T.; Parekh, Lina Patel; Stewart, Andrew K.; Thomas, Charles R.; Beltran, Robert A.; Lucci, Anthony; Green, Bettye; Ota, David; Nelson, Heidi.

In: Cancer, Vol. 106, No. 1, 01.01.2006, p. 188-195.

Research output: Contribution to journalArticle

Newman, Lisa A. ; Lee, Cheryl T. ; Parekh, Lina Patel ; Stewart, Andrew K. ; Thomas, Charles R. ; Beltran, Robert A. ; Lucci, Anthony ; Green, Bettye ; Ota, David ; Nelson, Heidi. / Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients : A report from the American College of Surgeons Oncology Group (ACOSOG) special populations committee. In: Cancer. 2006 ; Vol. 106, No. 1. pp. 188-195.
@article{55d28e4e4f8d4169842ae2b30ee6eeea,
title = "Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: A report from the American College of Surgeons Oncology Group (ACOSOG) special populations committee",
abstract = "BACKGROUND. Disparities in cancer outcome among different subsets of the American population related to ethnic background have been well documented. Clinical trials represent the most powerful strategy for improving cancer treatments, but racial and ethnic minority patients are frequently underrepresented among patients accrued to these protocols. Proof of comparable efficacy for a promising cancer therapy in different groups of patients requires diversity in the clinical trial populations so that study results will be generalizable. Appropriate targets for accrual of minority ethnicity patients have not previously been defined. METHODS. The National Cancer Database (NCDB) is maintained jointly by the American Cancer Society and the American College of Surgeons. Information submitted by tumor registries throughout the United States represents an estimated 70{\%} of newly diagnosed cancer cases. The authors analyzed NCDB reports on ethnic distribution of patients with breast, prostate, nonsmall cell lung, and colorectal cancer, stratified by stage of disease at diagnosis. RESULTS. African Americans with cancer of the breast and prostate had the most notable patterns of disproportionate representation among populations with advanced-stage disease. The authors compiled a table of suggested accrual targets for selected solid-organ cancers based on NCDB stage-specific reports. CONCLUSIONS. Clinical trial results will be more meaningful if participating patients reflect the site- and stage-specific populations that are under study. The authors recommended that clinical trial investigators incorporate accrual targets for minority ethnicity populations into the study design.",
keywords = "Breast cancer, Colorectal cancer, Disease stage, Ethnicity, Minority, National Cancer Data Base, Nonsmall cell lung cancer, Prostate cancer",
author = "Newman, {Lisa A.} and Lee, {Cheryl T.} and Parekh, {Lina Patel} and Stewart, {Andrew K.} and Thomas, {Charles R.} and Beltran, {Robert A.} and Anthony Lucci and Bettye Green and David Ota and Heidi Nelson",
year = "2006",
month = "1",
day = "1",
doi = "10.1002/cncr.21592",
language = "English (US)",
volume = "106",
pages = "188--195",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients

T2 - A report from the American College of Surgeons Oncology Group (ACOSOG) special populations committee

AU - Newman, Lisa A.

AU - Lee, Cheryl T.

AU - Parekh, Lina Patel

AU - Stewart, Andrew K.

AU - Thomas, Charles R.

AU - Beltran, Robert A.

AU - Lucci, Anthony

AU - Green, Bettye

AU - Ota, David

AU - Nelson, Heidi

PY - 2006/1/1

Y1 - 2006/1/1

N2 - BACKGROUND. Disparities in cancer outcome among different subsets of the American population related to ethnic background have been well documented. Clinical trials represent the most powerful strategy for improving cancer treatments, but racial and ethnic minority patients are frequently underrepresented among patients accrued to these protocols. Proof of comparable efficacy for a promising cancer therapy in different groups of patients requires diversity in the clinical trial populations so that study results will be generalizable. Appropriate targets for accrual of minority ethnicity patients have not previously been defined. METHODS. The National Cancer Database (NCDB) is maintained jointly by the American Cancer Society and the American College of Surgeons. Information submitted by tumor registries throughout the United States represents an estimated 70% of newly diagnosed cancer cases. The authors analyzed NCDB reports on ethnic distribution of patients with breast, prostate, nonsmall cell lung, and colorectal cancer, stratified by stage of disease at diagnosis. RESULTS. African Americans with cancer of the breast and prostate had the most notable patterns of disproportionate representation among populations with advanced-stage disease. The authors compiled a table of suggested accrual targets for selected solid-organ cancers based on NCDB stage-specific reports. CONCLUSIONS. Clinical trial results will be more meaningful if participating patients reflect the site- and stage-specific populations that are under study. The authors recommended that clinical trial investigators incorporate accrual targets for minority ethnicity populations into the study design.

AB - BACKGROUND. Disparities in cancer outcome among different subsets of the American population related to ethnic background have been well documented. Clinical trials represent the most powerful strategy for improving cancer treatments, but racial and ethnic minority patients are frequently underrepresented among patients accrued to these protocols. Proof of comparable efficacy for a promising cancer therapy in different groups of patients requires diversity in the clinical trial populations so that study results will be generalizable. Appropriate targets for accrual of minority ethnicity patients have not previously been defined. METHODS. The National Cancer Database (NCDB) is maintained jointly by the American Cancer Society and the American College of Surgeons. Information submitted by tumor registries throughout the United States represents an estimated 70% of newly diagnosed cancer cases. The authors analyzed NCDB reports on ethnic distribution of patients with breast, prostate, nonsmall cell lung, and colorectal cancer, stratified by stage of disease at diagnosis. RESULTS. African Americans with cancer of the breast and prostate had the most notable patterns of disproportionate representation among populations with advanced-stage disease. The authors compiled a table of suggested accrual targets for selected solid-organ cancers based on NCDB stage-specific reports. CONCLUSIONS. Clinical trial results will be more meaningful if participating patients reflect the site- and stage-specific populations that are under study. The authors recommended that clinical trial investigators incorporate accrual targets for minority ethnicity populations into the study design.

KW - Breast cancer

KW - Colorectal cancer

KW - Disease stage

KW - Ethnicity

KW - Minority

KW - National Cancer Data Base

KW - Nonsmall cell lung cancer

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=29744432215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29744432215&partnerID=8YFLogxK

U2 - 10.1002/cncr.21592

DO - 10.1002/cncr.21592

M3 - Article

C2 - 16333856

AN - SCOPUS:29744432215

VL - 106

SP - 188

EP - 195

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -